市場調査レポート

商品コード

1630593

非侵襲的出生前検査の市場規模、シェア、成長分析、製品別、検査方法別、技術別、妊娠リスク別、妊娠期間別、用途別、地域別 - 産業予測、2025～2032年

Non-Invasive Prenatal Testing Market Size, Share, Growth Analysis, By Product, By Testing Method, By Technology, By Pregnancy Risk, By Gestation Period, By Application, By Region - Industry Forecast 2025-2032

出版日: 2025年01月10日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

非侵襲的出生前検査（NIPT）の世界市場規模は2023年に38億米ドルと評価され、2024年の41億6,000万米ドルから2032年には86億7,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは9.6％で成長する見通しです。

主に非侵襲的出生前検査（NIPT）に焦点を当てた非侵襲的非経口スクリーニング市場は、技術の進歩と染色体異常の高いリスクと相関する母体年齢の上昇に牽引され、著しい成長を示しています。この遺伝子検査法は、母体血清中の胎児無細胞DNAを分析し、ダウン症候群やターナー症候群などの疾患の早期発見を可能にします。MaterniT21 PLUS、Harmony、Panoramaを含む様々なNIPTが現在世界的に広く利用可能です。NIPTに対する償還額の上昇と非侵襲的な方法へのシフトによって促進され、市場は拡大に向かっています。しかし、有資格者の不足や規制要件の厳しさといった課題が、進展の妨げになる可能性があります。新興市場、特にアジア太平洋地域は、この分野の成長に新たな機会をもたらしています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Berry Genomics Co. Ltd.（China）
BGI Genomics Co., Ltd.（China）
Eurofins LifeCodexx GmbH（Germany）
F. Hoffmann-La Roche Ltd.（Switzerland）
GE Healthcare（United States）
Natera, Inc.（United States）
Laboratory Corporation of America Holdings（LabCorp）（United States）
Illumina, Inc.（United States）
Myriad Genetics, Inc.（United States）
Quest Diagnostics Incorporated（United States）
Thermo Fisher Scientific Inc.（United States）
Sonic Healthcare Limited（Australia）
Centogene N.V.（Germany）
PerkinElmer, Inc.（United States）
Cordlife Group Limited（Singapore）

結論と推奨事項

Product Code: SQMIG35J2080

Global Non-Invasive Prenatal Testing (NIPT) Market size was valued at USD 3.8 billion in 2023 and is poised to grow from USD 4.16 billion in 2024 to USD 8.67 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).

The non-invasive parenteral screening market, predominantly focused on non-invasive prenatal testing (NIPT), is witnessing significant growth driven by advancements in technology and increasing maternal age, which correlates with higher risks for chromosomal abnormalities. This genetic testing method analyzes fetal cell-free DNA in maternal blood serum, enabling early detection of conditions such as Down syndrome and Turner syndrome. Various NIPTs, including MaterniT21 PLUS, Harmony, and Panorama, are now widely available globally. Facilitated by rising reimbursements for NIPT and a shift towards non-invasive methods, the market is poised for expansion. However, challenges such as a lack of qualified personnel and stringent regulatory requirements may impede progress. Emerging markets, especially in the Asia-Pacific region, present new opportunities for growth in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Invasive Prenatal Testing (Nipt) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Invasive Prenatal Testing (NIPT) Market Segmental Analysis

Global Non-Invasive Prenatal Testing (NIPT) Market is segmented by Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User and region. Based on Product, the market is segmented into Consumables, Reagents and Instruments. Based on Testing Method, the market is segmented into Ultrasound Detection, Biochemical Screening Tests and Cell-Free DNA in Maternal Plasma Tests. Based on Technology, the market is segmented into NGS, Array Technology, PCR and Others. Based on Pregnancy Risk, the market is segmented into High Risk, Average Risk and Low Risk. Based on Gestation Period, the market is segmented into 0-12 Weeks, 13-24 Weeks and 25-36 Weeks. Based on Application, the market is segmented into Trisomy, Microdeletion Syndrome and Others. Based on End User, the market is segmented into Hospitals, Clinics, Diagnostic Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Invasive Prenatal Testing (NIPT) Market

The Global Non-Invasive Prenatal Testing (NIPT) market is driven by the increasing demand for precise and advanced screening techniques that enable early detection of genetic disorders in infants. Companies are focusing on developing innovative noninvasive diagnostic solutions and forming strategic partnerships to enhance their presence in the market. Recent progress in human genome sequencing has significantly improved the identification of aneuploidies in newborns. Notably, Progenity, Inc. launched the Resura Prenatal Diagnostic for Monogenic Disease in 2019, marking a milestone as the first flexible, noninvasive test for single-gene conditions. Furthermore, many countries are adopting non-invasive prenatal screening protocols to effectively detect chromosomal abnormalities.

Restraints in the Global Non-Invasive Prenatal Testing (NIPT) Market

The growth of the Global Non-Invasive Prenatal Testing (NIPT) market faces several significant restraints, primarily stemming from economic and educational barriers. High testing costs, particularly in developing nations where prices range from USD 350 to USD 400, render these tests unaffordable for many, thus hindering widespread adoption. Additionally, a general lack of awareness regarding genetic disorders among the population in emerging markets further complicates acceptance. Coupled with decreasing per capita healthcare expenditure and insufficient reimbursement policies for these tests, these factors collectively contribute to a constrained growth environment for the NIPT market on a global scale.

Market Trends of the Global Non-Invasive Prenatal Testing (NIPT) Market

The Global Non-Invasive Prenatal Testing (NIPT) market is witnessing significant growth as healthcare trends increasingly favor non-invasive methodologies over traditional invasive procedures. Advances in technology and clinical validation have positioned NIPT as the preferred choice for prenatal screening, driven by its therapeutic benefits and cost-effectiveness. Regulatory frameworks in various countries, such as the Netherlands, have further reinforced the adoption of non-invasive diagnostics, establishing them as standard practice. This surge in utilization highlights a shift toward safer prenatal options, with NIPT rapidly gaining traction worldwide, despite the ongoing relevance of invasive tests for specific medical conditions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Product & CAGR (2025-2032)

Market Overview
Consumables
Reagents
Instruments

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Testing Method & CAGR (2025-2032)

Market Overview
Ultrasound Detection
Biochemical Screening Tests
Cell-Free DNA in Maternal Plasma Tests

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Technology & CAGR (2025-2032)

Market Overview
NGS
Array Technology
PCR
Others

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Pregnancy Risk & CAGR (2025-2032)

Market Overview
High Risk
Average Risk
Low Risk

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Gestation Period & CAGR (2025-2032)

Market Overview
0-12 Weeks
13-24 Weeks
25-36 Weeks

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Application & CAGR (2025-2032)

Market Overview
Trisomy
Microdeletion Syndrome
Others

Global Non-Invasive Prenatal Testing (NIPT) Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Diagnostic Laboratories
Others

Global Non-Invasive Prenatal Testing (NIPT) Market Size & CAGR (2025-2032)

North America (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
- US
- Canada
Europe (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Berry Genomics Co. Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI Genomics Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins LifeCodexx GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laboratory Corporation of America Holdings (LabCorp) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics Incorporated (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sonic Healthcare Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Centogene N.V. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cordlife Group Limited (Singapore)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

非侵襲的出生前検査の市場規模、シェア、成長分析、製品別、検査方法別、技術別、妊娠リスク別、妊娠期間別、用途別、地域別 - 産業予測、2025～2032年

Non-Invasive Prenatal Testing Market Size, Share, Growth Analysis, By Product, By Testing Method, By Technology, By Pregnancy Risk, By Gestation Period, By Application, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

世界の非侵襲的出生前検査（NIPT）市場規模：製品別

世界の非侵襲的出生前検査（NIPT）市場規模：検査方法別

世界の非侵襲的出生前検査（NIPT）市場規模：技術別

世界の非侵襲的出生前検査（NIPT）市場規模：妊娠リスク別

世界の非侵襲的出生前検査（NIPT）市場規模：妊娠期間別

世界の非侵襲的出生前検査（NIPT）市場規模：用途別

世界の非侵襲的出生前検査（NIPT）市場規模：エンドユーザー別

世界の非侵襲的出生前検査（NIPT）市場規模